NASDAQ:ACHL Achilles Therapeutics (ACHL) Stock Price, News & Analysis $1.48 0.00 (0.00%) As of 03/26/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Achilles Therapeutics Stock (NASDAQ:ACHL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Achilles Therapeutics alerts:Sign Up Key Stats Today's Range$1.48▼$1.4850-Day Range$1.37▼$1.4952-Week Range$0.63▼$1.51VolumeN/AAverage Volume568,222 shsMarket Capitalization$60.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAchilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Read More… Receive ACHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACHL Stock News HeadlinesAchilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC DeregistrationFebruary 28, 2025 | markets.businessinsider.comAchilles Therapeutics announces voluntary Nasdaq delisting, SEC deregistrationFebruary 28, 2025 | markets.businessinsider.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 25, 2025 | Crypto Swap Profits (Ad)Achilles Transfers Technology Assets From TRACERx NSCLC Study To AstraZeneca For $12 Mln, Stock UpDecember 24, 2024 | markets.businessinsider.comAchilles Therapeutics Announces Sale of Technology Assets to AstraZenecaDecember 24, 2024 | globenewswire.comAchilles Therapeutics PLC: Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketNovember 19, 2024 | finanznachrichten.deAchilles Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketNovember 19, 2024 | globenewswire.comAchilles Therapeutics PLC: Achilles Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | finanznachrichten.deSee More Headlines ACHL Stock Analysis - Frequently Asked Questions How have ACHL shares performed this year? Achilles Therapeutics' stock was trading at $1.14 at the beginning of the year. Since then, ACHL stock has increased by 29.8% and is now trading at $1.48. View the best growth stocks for 2025 here. How were Achilles Therapeutics' earnings last quarter? Achilles Therapeutics plc (NASDAQ:ACHL) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.41) earnings per share for the quarter, hitting the consensus estimate of ($0.41). When did Achilles Therapeutics IPO? Achilles Therapeutics (ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO. How do I buy shares of Achilles Therapeutics? Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Achilles Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Digital Turbine (APPS), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA). Company Calendar Last Earnings8/14/2024Today4/25/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACHL CIK1830749 Webwww.achillestx.com Phone44-0-20-8154-4600FaxN/AEmployees250Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.45% Return on Assets-47.68% Debt Debt-to-Equity RatioN/A Current Ratio6.04 Quick Ratio6.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.42Miscellaneous Outstanding Shares41,100,000Free Float38,889,000Market Cap$60.83 million OptionableNot Optionable Beta1.25 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ACHL) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.